Novo Nordisk's New Calculus: A Raised Forecast That Can't Mask the Competitive Arithmetic

Novo Nordisk's Q2 beat and improved guidance lift shares, but oral Wegovy sales miss and pipeline impairments temper investor enthusiasm.

For a company that spent years as the undisputed heavyweight of the obesity-drug market, Novo Nordisk is learning an uncomfortable lesson: better guidance doesn't automatically translate into investor enthusiasm. The Danish pharma giant closed Friday at €41.04, up 2.81 percent from Thursday's €39.92 — a bounce that leaves the stock hovering almost exactly at its 50-day moving average of €41.02. It's a stabilization, not a celebration, and the numbers behind the move tell a far more complicated story.

The Quarter That Shifted the Goalposts

The second quarter of 2026 delivered what the company needed operationally. Adjusted revenue climbed 7 percent at constant exchange rates, while adjusted operating profit rose 11 percent, buoyed by stronger GLP-1 volumes across multiple regions and favorable adjustments to US rebate agreements. That momentum prompted management to dramatically revise its full-year outlook: instead of the previous forecast of a 4 to 12 percent decline in revenue and operating profit, Novo Nordisk now guides toward a range of 0 to minus 6 percent. The shift is meaningful — the best-case scenario has moved from contraction to stagnation.

The restructuring program announced in the third quarter of 2025 is also tracking. The company-wide overhaul is expected to deliver DKK 8 billion in savings, and headcount has already fallen to roughly 66,700 full-time positions, a 15 percent reduction year over year.

The Oral Ambition and Its Growing Friction

The centerpiece of Novo Nordisk's growth narrative remains the oral Wegovy tablet. Since launch, more than 5 million prescriptions have been written in the US alone, and the rollout of the higher-dose Wegovy HD variant at 7.2 milligrams is underway. But the headline numbers obscure a nagging detail: quarterly sales of DKK 3.218 billion came in just shy of the DKK 3.267 billion analysts had penciled in. Small miss, outsized symbolism — even the flagship growth story is no longer clearing the bar without a struggle.

CEO Mike Doustdar defended the pill's economics during Wednesday's earnings call, but investors pressed on pricing pressure, the quality of the earnings beat, and whether the oral franchise can sustain momentum against Eli Lilly. Analysts cited by CNBC were measured in their assessment, attributing the quarterly improvement largely to rebate adjustments and temporary effects. The bigger strategic question — whether CagriSema, the combination therapy once hailed as the next major catalyst, can deliver — remains unresolved after another mixed clinical readout in the REDEFINE-4 study.

The Cost of the Pipeline's Bruises

The operational progress came with a hefty accounting toll. Novo Nordisk recorded non-cash impairments of DKK 6.3 billion on intangible assets in its research pipeline during the second quarter, with DKK 4.0 billion tied to the drug candidate Monlunabant alone. More charges are on the horizon: the Phase 3 ZEUS study of Ziltivekimab, which hit its IL-6 signaling target but failed on July 31 to reduce the risk of major cardiovascular events in patients with atherosclerosis, chronic kidney disease, and elevated inflammation, posted a hazard ratio of 0.99. Management has flagged another non-cash writedown in the third quarter — while insisting the adjusted operating profit guidance for the year remains intact.

The Competitive Arithmetic

The market's reassessment of Novo Nordisk isn't happening in a vacuum. Eli Lilly has extended its share of the US GLP-1 market to 60.9 percent, while Novo Nordisk has slipped to 38.8 percent. That gap is reflected in valuations: Novo Nordisk trades at a price-to-earnings ratio of 11, against Eli Lilly's 33. The market has fundamentally repriced the rivalry, stripping away the premium of invincibility the Danish company once commanded.

Technical indicators suggest a market searching for a floor without quite finding one. The relative strength index sits at 41.5 — neither oversold nor overbought — while annualized 30-day volatility of nearly 40 percent signals that turbulence remains the default setting. The stock sits roughly 27 percent below its late-January 52-week high of €54.86, with the 52-week low of €30.25 providing a distant support level about 32 percent further down.

Defense on Multiple Fronts

Novo Nordisk isn't standing still. A Dutch court issued an injunction on Wednesday barring Ceban Ziekenhuisfarmacie B.V. from selling a compounded semaglutide nasal spray that infringed on the company's intellectual property. The supplementary protection certificate secures semaglutide exclusivity until March 2031, with the base Ozempic patent expiring between 2031 and 2032. The company is also advancing a partnership with Vivani Medical on a semaglutide implant, in development since July 2026, signaling a strategic pivot toward oral and long-acting delivery formats.

The buyback program continues as well: through August 3, Novo Nordisk had repurchased roughly 27.06 million B-shares at an average price of DKK 278.35 under the DKK 15 billion program launched February 4, 2026, for a total transaction volume of DKK 7.53 billion.

A Stock in Transition

With over DKK 72 billion in profit last year, Novo Nordisk remains a cash-generative powerhouse. What it has lost is the market's assumption of invincibility. For investors, the stock has shifted from a momentum trade to a value-oriented pharma holding — one that, without a clinical breakthrough to counter Eli Lilly's pipeline dominance, may find its January highs out of reach for the foreseeable future. The consolidation phase looks more likely than a collapse, but the era of effortless outperformance is over.